磁共振弹性成像衍生硬度:鉴别胰腺良恶性肿块的潜在影像生物标志物
本前瞻性连续纳入研究对75例胰腺实性肿瘤患者行磁共振弹性成像(MRE)和扩散加权成像(DWI),比较肿块硬度、硬度比及血清CA19-9鉴别胰腺导管腺癌与良性肿瘤的诊断效能。胰腺导管腺癌的肿块硬度、硬度比和CA19-9均显著更高,三者联合AUC达0.9758。
要点
- 胰腺导管腺癌肿块硬度中位数3.795 kPa,显著高于其他胰腺肿块的2.359 kPa(P=0.0003)。
- 肿块硬度阈值>2.8211 kPa鉴别良恶性敏感度78.4%、特异度66.7%、阳性预测值82.9%、阴性预测值60%。
- 硬度比阈值>1.5117鉴别良恶性敏感度77.8%、特异度83.3%、阳性预测值90.3%、阴性预测值65.2%。
核心结论
- MRE依据机械特性在鉴别胰腺导管腺癌与其他胰腺实性肿块方面具有很好的临床潜力。
研究设计与样本
- 前瞻性连续纳入研究,纳入2021年7月至2023年1月间75例确诊胰腺实性肿瘤的成年患者,均行自旋回波-EPI序列的MRE和DWI检查。
关键影像表现/征象
- 在硬度图和ADC图上于局灶肿瘤处放置感兴趣区,获得MRE衍生肿块硬度、硬度比(肿块硬度与实质硬度之比)及DWI衍生ADC值。
- 胰腺导管腺癌肿块硬度为3.795(2.879-4.438)kPa,其他胰腺肿块为2.359(2.01-3.507)kPa,P=0.0003。
- 胰腺导管腺癌硬度比为1.939(1.562-2.511),其他胰腺肿块为1.187(1.031-1.453),P<0.0001。
- 胰腺导管腺癌血清CA19-9为276(31.73-1055),其他胰腺肿块为10.45(7.825-14.15),P<0.0001。
诊断标准与关键数值
- 肿块硬度鉴别胰腺导管腺癌与其他胰腺肿块的AUC为0.7895,阈值>2.8211 kPa时敏感度78.4%、特异度66.7%、阳性预测值82.9%、阴性预测值60%。
- 硬度比鉴别胰腺导管腺癌与其他胰腺肿块的AUC为0.8392,阈值>1.5117时敏感度77.8%、特异度83.3%、阳性预测值90.3%、阴性预测值65.2%。
- 血清CA19-9鉴别胰腺导管腺癌与其他胰腺肿块的AUC为0.9136。
- 肿块硬度、硬度比与血清CA19-9联合鉴别胰腺导管腺癌与其他胰腺肿块的AUC为0.9758。
临床应用与阅片要点
- 胰腺实性肿块MRE测得硬度>2.8211 kPa或硬度比>1.5117时,提示胰腺导管腺癌可能,可结合CA19-9提高鉴别效能。
- 肿块硬度、硬度比及CA19-9三者联合AUC为0.9758,高于任一单独指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study sought to determine the diagnostic performance of magnetic resonance elastography (MRE) for pancreatic solid masses, compared with diffusion-weighted imaging (DWI) and serum CA19-9, to establish a threshold for differentiating between pancreatic ductal adenocarcinoma (PDAC) and benign tumors in pancreas.
MATERIALS AND METHODS: Between July 2021 to January 2023, 75 adult patients confirmed with pancreatic solid tumors were enrolled in this prospective and consecutive study. All patients underwent MRE and DWI examinations that were both performed with a spin echo-EPI sequence. Stiffness maps and apparent diffusion coefficient (ADC) maps were generated, with MRE-derived mass stiffness and stiffness ratio (computing as the ratio of mass stiffness to the parenchyma stiffness) and DWI-derived ADC values obtained by placing regions of interest over the focal tumors on stiffness and ADC maps. Further analysis of comparing diagnostic performances was assessed by calculating the area under ROC curves.
RESULTS: PDAC had significantly higher tumor stiffness [3.795 (2.879-4.438) kPa vs. 2.359 (2.01-3.507) kPa, P = 0.0003], stiffness ratio [1.939 (1.562-2.511) vs. 1.187 (1.031-1.453), P < 0.0001] and serum CA19-9 level [276 (31.73-1055) vs. 10.45 (7.825-14.15), P < 0.0001] than other pancreatic masses. Mass stiffness, stiffness ratio and serum CA19-9 showed good diagnostic performance for differentiation with AUC of 0.7895, 0.8392 and 0.9136 respectively. The sensitivity/specificity/positive predictive value/negative predictive value for differentiating malignant from benign pancreatic tumors with mass stiffness (cutoff, > 2.8211 kPa) and stiffness ratio (cutoff, > 1.5117) were 78.4/66.7/82.9/60% and 77.8/83.3/90.3/65.2% respectively. The combined performance of Mass stiffness, stiffness ratio and serum CA19-9 got an AUC of 0.9758.
CONCLUSION: MRE holds excellent clinical potential in discriminating pancreatic ductal adenocarcinoma from other pancreatic solid masses according to their mechanical properties.
引用
- Liu, Chen, Zhang, et al. Magnetic resonance elastography-derived stiffness: potential imaging biomarker for differentiation of benign and malignant pancreatic masses. Abdom Radiol (NY). 2023. PMID: 37237155. doi:10.1007/s00261-023-03956-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。